MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

biosimilars

  • Home
  • biosimilars
Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients
Posted inHematology-Oncology news Oncology

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

Posted by By MedXY 08/30/2026
This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.
Read More
The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift
Posted inClinical Updates news Public Health Specialties

The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift

Posted by By MedXY 09/06/2025
The US FDA's unprecedented exemption of clinical efficacy studies for a ustekinumab biosimilar marks a transformative regulatory milestone, reshaping biosimilar development, market dynamics, and patient access worldwide.
Read More
  • Noncombustible Nicotine or Tobacco Product Use After Smoking Cessation and Major Vision-Impairing Diseases: Evidence from a Nationwide Cohort Study and Clinical Implications
  • Advancing Inner Ear Imaging: A Synchrotron-Based Deep Learning Network Outperforms Expert Segmentation in Clinical CT Scans
  • KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation: A Novel Biomarker for Early Detection of Pancreatic Cancer
  • Ensuring Lasting Impact: Strategies for Sustainable Implementation of Surgical Trials in Gynecologic Oncology
  • Determinants and Outcomes of Vessel Recanalization Following Acute Cervical Artery Dissection: Insights from an International Multicenter Cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top